Cell
Volume 69, Issue 1, 3 April 1992, Pages 111-117
Journal home page for Cell

Article
Developmental defects in gorlin syndrome related to a putative tumor suppressor gene on chromosome 9

https://doi.org/10.1016/0092-8674(92)90122-SGet rights and content

Abstract

Gorlin syndrome is an autosomal dominant disorder that predisposes to basal cell carcinomas of the skin, ovarian fibromas, and medulloblastomas. Unlike other hereditary disorders associated with cancer, it features widespread developmental defects. To investigate the possibility that the syndrome is caused by mutation in a tumor suppressor gene, we searched for loss of heterozygosity in 16 sporadic basal cell carcinomas, 2 hereditary basal cell carcinomas, and 1 hereditary ovarian fibroma and performed genetic linkage studies in five Gorlin syndrome kindreds. Eleven sporadic basal cell carcinomas and all 3 hereditary tumors had allelic loss of chromosome 9q31, and all informative kindreds showed tight linkage between the Gorlin syndrome gene and a genetic marker in this region. Loss of heterozygosity at this chromosomal location, particularly in hereditary tumors, implies that the gene is homozygously inactivated and normally functions as a tumor suppressor. In contrast, hemizygous germline mutations lead to multiple congenital anomalies.

References (46)

  • F. Sarto et al.

    No evidence of chromosomal instability in nevoid basal-cell carcinoma syndrome

    Mutat. Res.

    (1989)
  • P. Soriano et al.

    Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice

    Cell

    (1991)
  • M.A. Anderson et al.

    The use of cyclosporin A in establishing human EBV-transformed lymphoblastoid cell lines

    In Vitro

    (1984)
  • L.A. Applegate et al.

    Hypersensitivity of skin fibroblasts from basal cell nevus syndrome patients to killing by ultraviolet B but not by ultraviolet C radiation

    Cancer Res.

    (1990)
  • S.J. Bale et al.

    The relationship between head circumference and height in normal adults and in the nevoid basal cell carcinoma syndrome and neurofibromatosis type 1

    Am. J. Med. Genet.

    (1991)
  • I.D. Bassukus et al.

    Hyposensitivity of basal cell naevus syndrome dermal fibroblasts to ultraviolet A

    Lancet

    (1990)
  • D.E. Brash et al.

    A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma

  • W.K. Cavenee et al.

    Expression of recessive alleles by chromosomal mechanisms in retinoblastoma

    Nature

    (1983)
  • G.L. Chan et al.

    Cultured diploid fibroblasts from patients with nevoid basal cell carcinoma syndrome are hypersensitive to killing by ionizing radiation

    Am. J. Pathol.

    (1983)
  • T.R. Fears et al.

    Changes in skin cancer morbidity between 1971–1972 and 1977–1978

    J. Natl. Cancer Inst.

    (1982)
  • T. Featherstone et al.

    Studies on the radiosensitivity of cells from patients with basal cell naevus syndrome

    Am. J. Hum. Genet.

    (1983)
  • M.A. Ferguson-Smith et al.

    Multiple self-healing squamous epithelioma

    Birth Defects

    (1971)
  • S.H. Friend et al.

    A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma

    Nature

    (1986)
  • Cited by (389)

    • Hedgehog Signalling in Development and Disease

      2022, Encyclopedia of Cell Biology: Volume 1-6, Second Edition
    • Emerging trends in the treatment of advanced basal cell carcinoma

      2018, Cancer Treatment Reviews
      Citation Excerpt :

      In contrast, aberrant Hh pathway activation in BCC (as well as many medulloblastomas and rhabdomyosarcomas) does not require Hh ligand expression but instead depends on pathway-activating mutations in Hh pathway components such as SMO or PTCH1 [32,35]. BCC was first linked to aberrant Hh pathway signaling when mutations in the PTCH1 gene were identified as the driving mutation in patients with Gorlin syndrome, who often have numerous BCCs [36–39]. Subsequently, most spontaneous BCCs were found to have mutations in components of the Hh pathway that promote aberrant signaling, including inactivating mutations in PTCH1 in ≈ 85–90% and activating mutations in SMO in ≈ 10% [35,40,41].

    • Basal Cell Skin Cancer, Version 2.2024

      2023, JNCCN Journal of the National Comprehensive Cancer Network
    View all citing articles on Scopus
    View full text